Acumen Pharmaceuticals (ABOS) Accumulated Expenses (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Accumulated Expenses data on file, last reported at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 21.5% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 21.5% YoY), and the FY2025 full-year result was $10.1 million, up 52.26% from the prior year.
• Accumulated Expenses declined to $5.3 million in Q1 2026, from $10.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.6 million in Q2 2025 to a low of $2.4 million in Q2 2023.
• A 5-year average of $5.2 million and a median of $4.4 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 297.11% in 2022 and slipped 27.93% in 2023, its largest moves.
• Tracing ABOS's Accumulated Expenses over 5 years: stood at $3.4 million in 2022, then jumped by 92.51% to $6.4 million in 2023, then advanced by 2.57% to $6.6 million in 2024, then soared by 52.26% to $10.1 million in 2025, then slumped by 47.7% to $5.3 million in 2026.
• Business Quant data shows ABOS's Accumulated Expenses at $5.3 million in Q1 2026, $10.1 million in Q4 2025, and $7.8 million in Q3 2025.